5-氨基-4-苯基-2(3H)-噻唑硫酮 | 6964-10-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氨基-4-苯基-2(3H)-噻唑硫酮
• 英文名称: 5-Amino-2-mercapto-4-phenyl-thiazol
• 英文别名: 5-amino-4-phenyl-3H-thiazole-2-thione；5-amino-4-phenylthiazole-2(3H)-thione；5-amino-2-mercapto-4-phenylthiazole；5-amino-4-phenylthiazole-2-thiol；5-amino-4-phenyl-3H-1,3-thiazole-2-thione
• CAS: 6964-10-9
• 化学式: C₉H₈N₂S₂
• mdl: MFCD01766188
• 分子量: 208.308
• InChiKey: DFBLEVVSFACJOY-UHFFFAOYSA-N

物化性质

• 熔点：
  261-262 °C (decomp)
• 沸点：
  354.2±52.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  5-氨基-4-苯基-2(3H)-噻唑硫酮 在 硫酸 、 双氧水 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 3.0h， 生成 5-amino-2-(tert-butylsulfinyl)-4-phenylthiazole
  参考文献：
  名称：

  [EN] HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS
  [FR] DÉRIVÉS HÉTÉROCYCLIQUES CONVENANT COMME COMPOSÉS SE LIANT AUX INHIBITEURS DE PROTÉINES D'APOPTOSE

  摘要：

  本发明涉及式(I)的化合物，或其药学上可接受的盐、溶剂化合物，这些化合物与凋亡抑制蛋白(IAPs)结合。本发明的化合物可用作诊断和治疗剂，用于治疗增殖性疾病，如癌症，促进增殖细胞中的凋亡，并使细胞对凋亡诱导剂敏感。本发明还提供了具有式(VI)或(VII)的聚合物化合物，包括至少两个式(I)化合物的单体单位，或至少一个式(I)化合物的单体单位和实体E。本发明还涉及包含所述式(I)、(VI)和(VII)化合物的药物组合物以及在医学中使用所述化合物的用途。

  公开号：

  WO2009152824A1
• 作为产物：
  描述：

  二硫化碳 、 2-amino-2-phenylacetonitrile 生成 5-氨基-4-苯基-2(3H)-噻唑硫酮
  参考文献：
  名称：

  Cook et al., Journal of the Chemical Society, 1947, p. 1598,1607

  摘要：

  DOI：

文献信息

• Inhibitors of IAP
  申请人：Cohen Frederick

  公开号：US20060014700A1

  公开（公告）日：2006-01-19

  The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R 1 , R 2 , R 3 , R 4 , R 4 ′, R 5 , R 5 ′, R 6 and R 6 ′ are as described herein.

  这项发明提供了IAP的新型抑制剂，可作为治疗恶性肿瘤的治疗剂，其中化合物具有一般式I：其中X、Y、A、R1、R2、R3、R4、R4'、R5、R5'、R6和R6'如本文所述。
• Novel IL-5 inhibiting 6-azauracil derivatives
  申请人：——

  公开号：US20020072603A1

  公开（公告）日：2002-06-13

  The present invention is concerned with the compounds of formula 1 the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, p and q are 0, 1, 2, 3 or 4 and q is also 5; X is O, S, NR 3 or a direct bond; R 1 is hydrogen, hydroxy, halo, optionally substituted amino, optionally substituted C 1-6 alkyl, C 1-6 alkyloxy, C 3-7 cycloalkyl or aryl; R 2 is aryl, Het 1 , C 3-7 cycloalkyl, optionally substituted C 1-6 alkyl; and if X is O, S or NR 3 , then R 2 may also be a carbonyl or thiocarbonyl linked substituent; R 3 is hydrogen or C 1-4 alkyl; R 4 and R 5 independently are optionally substituted C 1-6 alkyl, halo, hydroxy, mercapto, C 1-6 alkyloxy, C 1-6 akylthio, C 1-6 alkylcarbonyloxy, aryl, cyano, nitro, Het 3 , R 6 or NR 7 R 8 ; R 6 is substituted sulfonyl or sulfinyl; R 7 and R 8 are hydrogen, optionally substituted C 1-4 alkyl, aryl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl, Het 3 and R 6 ; R 9 and R 10 are each independently selected from hydrogen, optionally substituted C 1-4 alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl, Het 3 and R 6 ; R 11 is hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C 1-4 alkyloxy, carboxyl, C 1-4 alkyloxycarbonyl, trihaloC 1-4 alkylsulfonyloxy, R 6 , NR 7 R 8 , C(═O)NR 7 R 8 , aryl, aryloxy, arylcarbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, phthalimide-2-yl, Het 3 and C(═O)Het 3 ; R 12 and R 13 are each independently selected from hydrogen, optionally substituted C 1-4 alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl and R 6 ; aryl is optionally substituted phenyl; Het 1 , Het 2 and Het 3 are optionally substituted heterocycles; to processes for their preparation and compositions comprising them. It further relates to their use as a medicine.

  本发明涉及公式1的化合物，包括N-氧化物、药学上可接受的加合盐以及其立体化异构体形式，其中p和q为0、1、2、3或4，q也可以为5；X为O、S、NR3或直接键；R1为氢、羟基、卤素、可选择取代的氨基、可选择取代的C1-6烷基、C1-6烷氧基、C3-7环烷基或芳基；R2为芳基、Het1、C3-7环烷基、可选择取代的C1-6烷基；如果X为O、S或NR3，则R2也可以是羰基或硫代羰基连接的取代基；R3为氢或C1-4烷基；R4和R5独立地为可选择取代的C1-6烷基、卤素、羟基、巯基、C1-6烷氧基、C1-6烷硫基、C1-6烷基羰氧基、芳基、氰基、硝基、Het3、R6或NR7R8；R6为取代磺酰基或亚砜基；R7和R8为氢、可选择取代的C1-4烷基、芳基、羰基或硫代羰基连接的取代基、C3-7环烷基、Het3和R6；R9和R10各自独立地选自氢、可选择取代的C1-4烷基、苯基、羰基或硫代羰基连接的取代基、C3-7环烷基、Het3和R6；R11为羟基、巯基、氰基、硝基、卤素、三卤甲基、C1-4烷氧基、羧基、C1-4烷氧羰基、三卤代C1-4烷基磺酰氧基、R6、NR7R8、C(═O)NR7R8、芳基、芳氧基、芳基羰基、C3-7环烷基、C3-7环烷氧基、邻苯二甲酰亚胺-2-基、Het3和C(═O)Het3；R12和R13各自独立地选自氢、可选择取代的C1-4烷基、苯基、羰基或硫代羰基连接的取代基、C3-7环烷基和R6；芳基为可选择取代的苯基；Het1、Het2和Het3为可选择取代的杂环；以及其制备方法和包含它们的组合物。进一步涉及它们作为药物的用途。
• Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs
  申请人：Lacrampe Fernand Armand Jean

  公开号：US20050090495A1

  公开（公告）日：2005-04-28

  The present invention is concerned with the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, p and q are 0, 1, 2, 3 or 4 and q is also 5; X is O, S, NR 3 or a direct bond; R 1 is hydrogen, hydroxy, halo, optionally substituted amino, optionally substituted C 1-6 alkyl, C 1-6 alkyloxy, C 3-7 cycloalkyl or aryl; R 2 is aryl, Het 1 , C 3-7 cycloalkyl, optionally substituted C 1-6 alkyl; and if X is O, S or NR 3 , then R 2 may also be a carbonyl or thiocarbonyl linked substituent; R 3 is hydrogen or C 1-4 allyl; R 4 and R 5 independently are optionally substituted C 1-6 alkyl, halo, hydroxy, mercapto, C 1-6 alkyloxy, C 1-6 alkylthio, C 1-6 alkylcarbonyloxy, aryl, cyano, nitro, Het 3 , R 6 or NR 7 R 8 ; R 6 is substituted sulfonyl or sulfinyl; R 7 and R 8 are hydrogen, optionally substituted C 1-4 alkyl, aryl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl, Het 3 and R 6 ; R 9 and R 10 are each independently selected from hydrogen, optionally substituted C 1-4 alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl, Het 3 and R 6 ; R 11 is hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C 1-4 alkyloxy, carboxyl, C 1-4 alkyloxycarbonyl, trihaloC 1-4 alkylsulfonyloxy, R 6 , NR 7 R 8 , C(═O)NR 7 R 3 , aryl, aryloxy, arylcarbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, phthalimide-2-yl, Het 3 and C(═O)Het 3 ; R 12 and R 13 are each independently selected from hydrogen, optionally substituted C 1-4 alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C 3-7 cycloalkyl and R 6 ; aryl is optionally substituted phenyl; Het 1 , Het 2 and Het 3 are optionally substituted heterocycles; to processes for their preparation and compositions comprising them. It further relates to their use as a medicine.

  本发明涉及式子的化合物，其中N-氧化物，药学上可接受的加成盐和其立体化学异构体，p和q为0、1、2、3或4，而q也可以为5；X为O、S、NR3或直接键；R1为氢、羟基、卤素、可选取代氨基、可选取代的C1-6烷基、C1-6烷氧基、C3-7环烷基或芳基；R2为芳基、Het1、C3-7环烷基、可选取代的C1-6烷基；如果X为O、S或NR3，则R2还可以是一个与羰基或硫代羰基连接的取代基；R3为氢或C1-4烯丙基；R4和R5独立地为可选取代的C1-6烷基、卤素、羟基、巯基、C1-6烷氧基、C1-6烷硫基、C1-6烷基羰氧基、芳基、氰基、硝基、Het3、R6或NR7R8；R6为取代磺酰基或亚磺酰基；R7和R8为氢、可选取代的C1-4烷基、芳基、与羰基或硫代羰基连接的取代基、C3-7环烷基、Het3和R6；R9和R10各自独立地选自氢、可选取代的C1-4烷基、苯基、与羰基或硫代羰基连接的取代基、C3-7环烷基、Het3和R6；R11为羟基、巯基、氰基、硝基、卤素、三卤甲基、C1-4烷氧基、羧基、C1-4烷氧基羰基、三卤代C1-4烷基磺酰氧基、R6、NR7R8、C（═O）NR7R3、芳基、芳氧基、芳基羰基、C3-7环烷基、C3-7环烷氧基、邻二苯酰胺基-2-基、Het3和C（═O）Het3；R12和R13各自独立地选自氢、可选取代的C1-4烷基、苯基、与羰基或硫代羰基连接的取代基、C3-7环烷基和R6；芳基为可选取代的苯基；Het1、Het2和Het3为可选取代的杂环；以及制备它们的方法和包含它们的组合物。此外，本发明还涉及它们作为药品的用途。
• INHIBITORS OF IAP
  申请人：Cohen Frederick

  公开号：US20100256115A1

  公开（公告）日：2010-10-07

  The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R 1 , R 2 , R 3 , R 4 , R 4 ′, R 5 , R 5 ′, R 6 and R 6 ′ are as described herein.

  该发明提供了一种新型IAP抑制剂，可用作治疗恶性肿瘤的治疗剂，其中该化合物具有一般式I，其中X，Y，A，R1，R2，R3，R4，R4'，R5，R5'，R6和R6'如此描述。
• IAP BINDING COMPOUNDS
  申请人：Lundorf Mikkel Dybro

  公开号：US20110230419A1

  公开（公告）日：2011-09-22

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, that bind to Inhibitor of Apoptosis Proteins (IAPs). The compounds of the invention may be used as diagnostic and therapeutic agents in the treatment of proliferative diseases, such as cancer, for promoting apoptosis in proliferating cells, and for sensitizing cells to inducers of apoptosis. The present invention furthermore provides a polymeric compound of formulas (VI) or (VII), comprising either at least two monomeric units of compounds of formula (I), or at least one monomeric unit of a compound of formula (I) and an entity E. The present invention further relates to pharmaceutical compositions comprising said compounds of formulas (I), (VI), and (VII) and the use of said compounds in medicine.

  本发明涉及式(I)的化合物，或其药学上可接受的盐、溶剂化合物或前药，其与凋亡抑制蛋白（IAPs）结合。本发明的化合物可用作诊断和治疗增生性疾病，例如癌症，促进增殖细胞的凋亡，并使细胞对凋亡诱导剂敏感。本发明还提供式(VI)或(VII)的聚合物化合物，其中包括至少两个式(I)的单体单位，或至少一个式(I)的单体单位和一个实体E。本发明还涉及包含上述化合物的药物组合物，以及在医学中使用上述化合物的用途。